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Abstract
Background: The second-generation cryoballoon (CB2) provides effective and durable pulmonary 
vein isolation (PVI) associated with encouraging and reproducible clinical outcome data. The latest-
-generation cryoballoon (CB3) incorporates a 40% shorter distal tip, thus allowing for an increased rate 
of PVI real-time signal recording and facilitating individualized ablation strategies taking the time-to-
-effect (TTE) into account. However, whether this characteristic translates into favorable clinical success 
has not been evaluated yet. Herein was investigated 1-year clinical success after CB3 in comparison to 
CB2 based-PVI.
Methods: One hundred and ten consecutive patients with paroxysmal or short-standing persistent 
atrial fibrillation (AF) underwent CB2 (n = 55 patients) -or CB3 (n = 55 patients) -based PVI. The 
freeze-cycle duration was set to TTE + 120 s if TTE could be recorded, otherwise a fixed freeze-cycle 
duration of 180 s was applied. 
Results: A total of 217/218 (99%, CB3) and 217/217 (100%, CB2) pulmonary veins (PV) were 
successfully isolated. The real-time PVI visualization rate was 69.2% (CB3) and 54.8% (CB2;  
p = 0.0392). The mean freeze-cycle duration was 194 ± 77 s (CB3) and 206 ± 85 s (CB2; p = 0.132), 
respectively. During a median follow-up of 409 days (interquartile range [IQR] 378–421, CB3) and  
432 days (IQR 394–455, CB2) 73.6% (CB3) and 73.1% of patients (CB2) remained in stable sinus 
rhythm after a single procedure (p = 0.806).
Conclusions: A higher rate of real-time electrical PV recordings was seen using the CB3 as compared 
to CB2. There was no difference in 1-year clinical follow-up. (Cardiol J 2019; 26, 4: 368–374)
Key words: atrial fibrillation, pulmonary vein isolation, cryoballoon, long-term outcome
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Introduction
The second-generation cryoballoon (CB2, Arc-
tic Front Advance, Medtronic, Inc., Minneapolis, 
MN, USA) for pulmonary vein isolation (PVI) has 
demonstrated high procedural success rates and 
convincing clinical outcome data for patients with 
paroxysmal (PAF) and persistent atrial fibrillation 
(persAF) [1–4]. The “Fire And Ice” trial proved 
non-inferiority of CB2- to radiofrequency (RF)- 
-based PVI with regard to efficacy and safety for 
treatment of patients with PAF [5]. In consequence 
the latest AF guidelines state that PVI should be 
performed using either RF or CB catheters [6]. 
Current ablation strategies predominantly apply 
fixed freeze-cycle durations of 180–240 s, often-
times followed by a bonus-freeze cycle. Recently 
protocols were modified aiming for shorter and few-
er CB-applications and demonstrated comparable 
clinical outcomes [7, 8]. After identifying the time 
to pulmonary vein (PV) isolation (time-to-effect 
[TTE]) as an essential indicator for durable PVI 
latest ablation strategies have been implemented 
the individual TTE [9]. The long distal tip of the 
CB2 limits proper visualization of PV since it pre-
vents proximal positioning of the circular mapping 
catheter (Achieve, Medtronic) in close proximity 
to the CB’s surface. The third-generation cryobal-
loon (CB3, Arctic Front Advance ST, Medtronic) 
incorporates a 40% shorter tip facilitating a more 
proximal Achieve position. As a consequence 
initial studies found a higher rate of real-time PV 
recordings when utilizing the CB3 compared to 
CB2 [9–11]. However, whether this characteristic 
translates into favorable 1-year clinical success has 
not been evaluated yet. Herein was investigated 
the 1-year clinical outcomes after CB3 in compari-
son to CB2 based-PVI. 
Methods
Inclusion and exclusion criteria 
Consecutive patients with symptomatic, drug-
refractory PAF or short standing PersAF (duration 
≤ 3 months) consented to CB-based PVI and were 
treated with second-generation cryoballoon (CB2 
group, control), followed by 55 consecutively treat-
ed patients with the third-generation cryoballoon 
(CB3 group). Data on acute success of a limited 
number of patients was published before [9]. Ex-
clusion criteria were prior left atrial (LA) ablation 
attempts, a LA diameter > 60 mm, severe valvular 
heart disease or contraindications to postinterven-
tional oral anticoagulation. Transesophageal echo-
cardiography was performed in all patients prior to 
PVI to rule out intracardiac thrombi and to assess 
LA diameter. No further pre-procedural imaging 
was performed. The procedure was performed in 
patients on vitamin K antagonists under thera-
peutic international normalized ratio (INR) values 
of 2–3. New oral anticoagulants were stopped 
1 day prior to the procedure and continued 6 h post 
ablation. All patients gave written informed con-
sent and all patient information was anonymized. 
The study was approved by the local ethic’s board 
(ethical review board number: WF-028/15) and was 
performed in accordance with ethical standards laid 
down in the 1964 Declaration of Helsinki and its 
later amendments.
Intraprocedural management
The intraprocedural management has been 
described in detail in previous studies by the pre-
sent group [4, 9, 12]. In brief, the procedure was 
performed under deep sedation using midazolam, 
sufentanyl and propofol. Prior to transseptal punc-
ture one diagnostic catheter was introduced via the 
right femoral vein and positioned within the coro-
nary sinus (7 F, Webster TM, Biosense Webster, 
Inc. Diamond Bar, CA, USA). Single transseptal 
puncture was performed under fluoroscopic guid-
ance using a modified Brockenbrough technique 
and an 8.5 F transseptal sheath (SL1, St. Jude 
Medical, Inc., St. Paul, MN, USA). Selective PV 
angiography was performed to identify the PV 
ostia. The transseptal sheath was exchanged over 
a guidewire for a 12 F steerable sheath (Flexcath 
Advance, Medtronic). After transseptal puncture 
heparin boluses were administered targeting an 
activated clotting time of > 300 s. 
Cryoballoon-based PVI
The 28 mm CB was advanced into the LA 
via the 12 F steerable sheath using the Achieve 
catheter (20 mm diameter, Medtronic, Inc.) for 
guidance. The CB was inflated proximal to the PV 
ostium followed by gentle push aiming for complete 
PV sealing. Occlusion of the PV ostium was verified 
by contrast dye injections. Standard freeze-cycle 
duration was TTE + 120 s. If the TTE could not 
be visualized, the freeze-cycle duration was set to 
180 s. No additional bonus freeze-cycle was applied. 
The procedural endpoint was defined as persistent 
PVI verified by Achieve catheter (Medtronic, Inc.) 
recordings after the last CB application. 
A spiral temperature probe (Sensitherm, St. 
Jude Medical) was advanced into the esophagus 
to monitor esophageal temperatures during each 
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energy application. The intraluminal esophageal 
temperature cut-off was set at 15°C. During en-
ergy delivery along the septal PVs, continuous 
phrenic nerve (PN) pacing was performed using 
a diagnostic catheter introduced into the superior 
vena cava (7 F, Webster TM, Biosense Webster, 
Inc.). Pacing was set at maximum output and pulse 
width (12 mA, 2.9 ms) and a cycle length of 1200 
ms. PN capture was monitored by tactile feedback 
of diaphragmatic contraction and assessment of the 
right diaphragmatic compound motor action po-
tential (CMAP). Energy delivery was interrupted 
immediately if weakening or loss of diaphragmatic 
contraction was noted or a decrease of CMAP am-
plitude of ≥ 30% was seen. In case of persistent 
PN palsy, no further cryoenergy was delivered to 
septal PVs. 
Postprocedural care
Following ablation, all patients underwent 
transthoracic echocardiography to rule out a peri-
cardial effusion. Low molecular-weight heparin was 
administered in patients on vitamin K antagonists 
and an INR < 2.0 until a therapeutic INR of 2–3 was 
achieved. New oral anticoagulants were re-initiated 
6 h post ablation. Anticoagulation was continued for 
at least 3 months and continued thereafter based 
on the individual CHA2DS2-VASc score. Previously 
ineffective antiarrhythmic drugs were continued 
for 3 months post ablation [4, 12]. 
All patients were treated with proton-pump 
inhibitors for 6 weeks. 
Clinical follow-up and study endpoints
Following a blanking period of 3 months, 
patients completed outpatient clinic visits at 
3, 6 and 12 months and thereafter in 6-month inter-
vals which included electrocardiograms (ECGs) and 
24 h-Holter ECGs. In addition, regular telephonic 
interviews were performed. Additional outpatient 
clinic visits were immediately initiated in case of 
symptoms suggestive of recurrent arrhythmia. 
The primary endpoint was defined as recurrence 
of any symptomatic or documented AF episode 
> 30 s following a blanking period of 3 months. 
Secondary endpoints were acute procedural data 
and procedure related complications such as phren-
ic nerve palsy, cerebral embolism, pericardial effu-
sion/tamponade or atrioesophageal fistula.
Statistical analysis
Differences in metric variables between the 
two groups were analyzed with t-test if data were 
normally distributed, and otherwise with Wilcoxon- 
-Mann-Whitney test. Differences between cat-
egorical variables were evaluated using c2 test 
or the Fisher exact test in case of small expected 
cell frequencies. PVI data was analyzed using 
mixed models. Linear mixed models were used for 
continuous data. Generalized linear mixed models 
were used for binary or count data. A hierarchical 
logistic regression model was applied for binary 
data. A Poisson distribution was assumed for count 
data. All p-values are two-sided and a p-value 
< 0.05 was considered significant. All calculations 
were performed with statistical analysis software 
SAS (SAS Institute Inc., version 9.3, Cary, NC, 
USA) [12]. 
Results
Patient characteristics
A total of 110 consecutive patients underwent 
28 mm CB-based PVI utilizing the CB2 (n = 55) 
and CB3 (n = 55) (Fig. 1). Patient baseline char-
acteristics are depicted in Table 1. No differences 
were identified between the groups.
Acute ablation results
Acute ablation results are depicted in Table 2. 
In 110 patients, a total of 435 PVs were identified 
and targeted. One right superior pulmonary vein 
(CB3 group) was not isolated due to phrenic nerve 
palsy during CB application along the ipsilateral 
right inferior pulmonary vein. All other PVs were 
successfully isolated (434/435, 99.8%). Real-time 
PVI was visualized in 69.2% of patients in the CB3 
and in 54.8% of patients in the CB2 group, re-
spectively (p = 0.0392). A significant difference 
regarding the mean minimal CB temperatures was 
assessed (–45°C, CB3 and –48°C, CB2; p < 0.0001). 
Yet, no difference was found for the mean total 
number of CB freeze-cycles per PV until PVI, the 
incidence of PVI after first CB freeze-cycle, the mean 
TTE, total freeze-time applied, mean CB tempera-
ture after 30 s of the freeze-cycle, or mean minimal 
esophageal temperature. Furthermore, no differences 
were found for total procedure time, total fluoroscopy 
time, and total amount of contrast dye (Table 2). 
All procedures were performed by three highly 
experienced operators and no differences were 
observed with regard to catheter maneuverability 
and stability.
Peri- and postprocedural complications
Transient PN palsy occurred in 1/55 (1.8%) 
patients in the CB3 group during energy delivery 
along the RIPV with full recovery of nerve function 
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after 15 min. No pericardial effusion, pericardial 
tamponade, symptomatic PV stenosis, transient 
ischemic attack/stroke, or atrioesophageal fistula 
were observed in any group. 
Clinical follow-up
Clinical 1-year follow-up was obtained in 
105/110 (95.5%) patients, while 5/110 (4.5%) 
patients were lost to follow-up. During a me-
dian follow-up of 409 (interquartile range [IQR] 
378–421, CB3) days and 432 days (IQR 394– 
–455, CB2) 73.6% of patients (CB3) and 73.1% 
of patients (CB2) remained in stable sinus rhythm 
(p = 0.806) following a single 28 mm CB-based 
PVI procedure including a 3-month blanking period 
(Fig. 2).
Table 1. Baseline characteristics
Variable All CB3 CB2
Patients 110 55 55
Age [years] 62.1 ± 11.4 60.4 ± 11.1 63.8 ± 11.5
Body mass index [kg/m2] 27.5 ± 4.87 28.3 ± 4.9 26.7 ± 4.7
Female gender 33 (70%) 16 (70.9%) 17 (69.1%)
Paroxysmal AF 71 (64.6%) 34 (61.8%) 37 (67.3%)
Short persistent AF 39 (34.5) 21 (38.2) 18 (32.7)
Duration of AF [months] 24 (12, 48) 24 (14, 48) 16.5 (7.5, 48)
LA-size [mm] 45.0 ± 6 45.9 ± 7 44.1 ± 5.7
Congestive heart failure 12 (11%) 8 (6%) 4 (7%)
Arterial hypertension 69 (63%) 35 (64%) 34 (62%)
Diabetes mellitus type 2 12 (11%) 9 (16%) 3 (5.5%)
Previous TIA/stroke 7 (6%) 3 (5%) 4 (7%)
Coronary artery disease 12 (11%) 4 (7%) 8 (6%)
CHA2DS2-VASc score 2.0 (1.0, 2.0) 2.0 (1.0, 2.0) 2.0 (1.0, 2.0)
EHRA classification 2.0 (2.0, 3.0) 2.0 (2.0, 3.0) 2.0 (2.0, 3.0)
Values expressed as number (percentage), mean ± standard deviation or median (25th, 75th percentiles) as appropriate. Test of no regression 
found no differences between the groups (p = 0.389). AF — atrial fibrillation; CB2 — second-generation cryoballoon; CB3 — third-generation 
cryoballoon; EHRA — European Heart Rhythm Association; LA — left atrium; TIA — transient ischemic attack
Figure 1. Flow-chart; AF — atrial fibrillation; PVI — pulmonary vein isolation; SSR — stable sinus rhythm.
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Discussion
The current study set out to compare proce-
dural characteristics and acute and 1-year clinical 
efficacy of the novel 28 mm CB3 to the CB2 for PVI 
in patients with PAF and short-standing persAF. The 
major findings are 1) the CB3 provides an identical 
rate of acute PVI during the index freeze-cycle as 
the CB2, 2) the incidence of PVs with real-time 
signal recordings was significantly higher in the 
CB3 group, 3) procedure and fluoroscopy times 
were not different although a trend towards shorter 
freeze-cycles was observed in the CB3 group when 
considering the individual TTE, and 4) there were 
no statistical significant differences in the 1-year 
clinical outcomes between both groups.
Recent studies focusing on CB2 ablation dem-
onstrated a high rate of PVI (84–90%) during the 
index freeze cycle [12–14], superior 1- and 2-year 
clinical outcomes as compared to  first-generation 
CB even if  “no-bonus” freeze protocols or a short-
er freeze-cycle durations were applied, and a high 
Table 2. Procedural details.
Variable All CB3 CB2 p
Number of PVs 435 218 217
Total CB cycles until PVI 1.1 ± 0.5 1.1 ± 0.6 1.1 ± 0.4 0.128
Number of isolated PVs 434/435 (99%) 217/218 (99%) 217/217 (100%) 0.316
Number of isolated PVs after 1st cycle 390/435 (89.7%) 191/218 (88%) 199/217 (92%) 1.000
Minimal temperature [°C] –47 ± 6 –45 ± 6 –48 ± 6 < 0.0001
Minimal esophageal-temperature [°C] 33.7 ± 4 33.9 ± 4 33.5 ± 4 0.474
Real-time recordings 270 (62.1%) 151 (69.2%) 119 (54.8%) 0.0392
Time to PVI [s] 47 ± 32 48 ± 32 45 ± 32 1.000
Temperature after 30 s CB cycle duration [°C] –31 ± 10 –29 ± 11 –32 ± 9 0.075
Duration of total freezing time [s] 200 ± 81 194 ± 77 206 ± 85 0.132
Total procedure time [min] 92 ± 28 94 ± 30 90 ± 27 0.525
Total flouroscopy time [min] 17 (13, 23) 19 (14, 27) 16 (13, 20) 0.389
Total amount of contrast [mL] 115 ± 25 115 ± 25 116 ± 25 0.792
Values expressed as number (percentage), mean ± standard deviation or median (25th, 75th percentiles) as appropriate. CB — 28 mm cryoballoon; 
CB2 — second-generation cryoballoon; CB3 — third-generation cryoballoon; PV(s) — pulmonary vein(s); PVI — pulmonary vein isolation
Figure 2. Recurrence free survival between the groups (n = 110 patients). Kaplan-Meier curve demonstrating the 
relative proportion of patients in stable sinus rhythm following initial pulmonary vein isolation (PVI) using the third-
-generation cryoballoon (CB3) compared to the second-generation cryoballoon (CB2) including a 3-month blanking 
period. During a median follow-up of 409 (interquartile range [IQR] 378–421, CB3) days and 432 days (IQR 394–455, 
CB2) 73.6% of patients (CB3) and 73.1% of patients (CB2) remained in stable sinus rhythm without any differences 
between the groups (p = 0.806) following a single 28 mm CB-based PVI procedure including a 3-month blanking 
period. No significant difference was found for the follow-up duration (p = 0.071).
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rate of durable PVI as demonstrated in patients 
undergoing repeat procedures for recurrent atrial 
tachyarrhythmias after previous second-generation 
CB ablation [15]. Modified ablation strategies tak-
ing the individual TTE into account are currently 
under investigation. An essential prerequisite for 
TTE-based ablation protocols is a considerably high 
incidence of real-time PV potential recordings. In-
corporating individual TTE into ablation protocols 
may reduce total energy transfer per PV which in 
turn may contribute to an even better safety-profile 
of CB-based PVI [16].
The current study confirms that a high rate 
of PVI with initial freeze-cycle can be achieved 
with both, the CB3 and CB2 (86% vs. 92%, 
p = 0.14). Although mean minimal balloon-temper-
ature measured when applying CB2 was significant-
ly lower than with CB3, acute efficacy was similar 
for both CB generations. Observed differences in 
minimal balloon-temperatures might be caused by 
a slightly changed position of the temperature 
probe of CB3 to a more proximal position compared 
to CB2. This fact causes a minimally longer dis-
tance of the returning gas to the temperature probe 
and therefore higher returning gas temperatures. 
Of note, no significant difference was assessed be-
tween both groups for balloon temperature reached 
at 30 s of the respective freeze-cycle [17]. There 
was also no difference when comparing the lowest 
intraluminal esophageal temperatures. These facts 
additionally support the observation of an equal 
acute efficacy of both CB-generations. 
Characteristic complications of CB-based PVI 
such as PN palsy or a significant drop in intraluminal 
esophageal temperatures potentially resulting in 
esophageal thermal injury typically occur at later 
stages of the freeze-cycles [18]. Therefore, recent 
ablation protocols aim not only to reduce of the 
number of freeze-cycles per PV but especially for 
shorter freeze-cycle durations to further improve 
the safety profile of CB-based PVI [17]. The Achieve 
catheter provides online visualization of PV signals. 
However, the relatively long distal tip of CB2 may 
prevent proper positioning of the Achieve catheter 
at proximal PV ostium, thus limiting real-time sig-
nal recording in a considerable number of PVs and 
individualized ablation protocols considering TTE 
[14, 19]. The novel CB3 was modified and incorpo-
rates a 40% shorter distal tip, potentially facilitating 
more proximal positioning of Achieve-catheter and 
increased rates of real-time PV signal recordings. 
Accordingly, the current study found a significantly 
higher percentage of real-time PVI recordings for 
CB3 as compared to CB2 group (69.2% vs. 54.8%, 
p = 0.0392) and in consequence allowed for a higher 
percentage of PVs in which individual TTE was 
taken into account without affecting overall clinical 
outcomes. In conclusion, this means that a shorter 
balloon tip will further facilitate individualized abla-
tion strategies and might further improve the safety 
profile of CB ablation due to shorter but efficient 
energy transfer [20]. Although one group reported 
on balloon dislodgement during hockey stick ma-
neuvers caused by the shortened distal tip of CB3 
[21], no differences concerning catheter stability 
and catheter maneuverability have been observed 
in the present analysis. Although CB3 was taken 
from the market it would be desirable that future CB 
generations again incorporate a shortened distal tip.
Limitations of the study
The current study is a retrospective analysis 
and is based on a single-center experience in 
a limited number of patients. Since this is not 
a randomized controlled trial with proper power 
calculations any conclusions regarding outcome 
are hypothesis-generating only. Currently, the CB3 
is not available. However, future CB generations 
might again incorporate a shorter balloon tip.
Conclusions
According to available research, this is the 
first study reporting on procedural characteristics 
and 1-year clinical outcomes of CB3- as com-
pared to CB2-based PVI. While demonstrating 
comparable acute and 1-year efficacy, the CB3 
provides a significantly increased rate of real-time 
PV-recordings as compared to CB2 and thus fa-
cilitates individual ablation strategies considering 
individual TTE.
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